Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ImmunoCellular Therapeutics, Ltd.IMUC · Entity 165907 | Director | June 06, 2018 | June 08, 2018 |
| Kairos Pharma, LTD.KAPA · Entity 8244 | Director · CEO and Chairman · 10% owner | October 08, 2025 | November 26, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ImmunoCellular Therapeutics, Ltd.
Report date June 06, 2018 · Filed June 08, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 120,250 |
Reported balance
After 2018-06-06 transaction · row 1
1 source rowRow 1 · 2018-06-06 · Grant · Acquired 120,000 · Balance 120,250 F1: Each restricted stock unit represents a contingent right to receive one share of ImmunoCellular Therapeutics Ltd. common stock. F2: The restricted stock unit shall be fully vested and immediately exercisable on the grant date. |
| Common StockSEC Table I · non-derivative | IndirectBy Family Trust | 258 |
Reported balance
Holding disclosure · report date 2018-06-06 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 258 |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of ImmunoCellular Therapeutics Ltd. common stock.
F2: The restricted stock unit shall be fully vested and immediately exercisable on the grant date.
Kairos Pharma, LTD.
Report date October 08, 2025 · Filed November 26, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 230,105 |
Reported balance
After 2025-10-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-10-08 · Grant · Acquired 190,840 · Balance 230,105 F1: Represents 190,840 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 190,840 RSUs are scheduled to vest in full on the first anniversary of the grant date. F2: Consists of (1) 34,599 shares of common stock (2) 195,506 RSUs which remain subject to vesting. |
| COMMON STOCKSEC Table I · non-derivative | IndirectBy Self as Trustee for The Yu Family Trust | 5,316,572 |
Reported balance
Holding disclosure · report date 2025-10-08 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5,316,572 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 190,840 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 190,840 RSUs are scheduled to vest in full on the first anniversary of the grant date.
F2: Consists of (1) 34,599 shares of common stock (2) 195,506 RSUs which remain subject to vesting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 08, 2025 Filed Nov 26, 2025 17:24 UTC | Kairos Pharma, LTD. KAPA · Entity 8244 | GrantCOMMON STOCK | 190,840 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-025197 · ownership.xml · nonDerivative · entry 1 Yu John S · CIK 0001550545 · Director · CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,105 F1 · shares: Represents 190,840 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 190,840 RSUs are scheduled to vest in full on the first anniversary of the grant date. F2 · balance_after: Consists of (1) 34,599 shares of common stock (2) 195,506 RSUs which remain subject to vesting. Read SEC document |
| January 01, 2025 Filed Feb 24, 2025 18:51 UTC | Kairos Pharma, LTD. KAPA · Entity 8244 | GrantCOMMON STOCK | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-008105 · ownership.xml · nonDerivative · entry 1 Yu John S · CIK 0001550545 · Director · CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,355,838 F1 · shares: Represents 14,000 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 14,000 RSUs are scheduled to vest in one third increments on each of 01/01/2025, 09/16/2025, and 09/16/2026. Accordingly, 4,667 RSUs have vested as of the date hereof. F2 · balance_after: Consists of (1) 5,346,504 shares of common stock and (2) 9,334 RSUs which remain subject to vesting. Read SEC document |
| November 20, 2024 Filed Nov 21, 2024 21:53 UTC | Kairos Pharma, LTD. KAPA · Entity 8244 | PurchaseCOMMON STOCK | 4,000 | $1.44 | $5,760.00 |
DisclosureSEC source: 0001493152-24-047261 · ownership.xml · nonDerivative · entry 1 Yu John S · CIK 0001550545 · Director · CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,341,837 Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 16:07 UTC | ImmunoCellular Therapeutics, Ltd. IMUC · Entity 165907 | GrantCommon Stock | 120,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-036656 · doc4.xml · nonDerivative · entry 1 Yu John S · CIK 0001550545 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,250 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of ImmunoCellular Therapeutics Ltd. common stock. F2 · shares: The restricted stock unit shall be fully vested and immediately exercisable on the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.